ADAMTS-12 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-12 (UniProt P58397), HEK293-expressed. Suitable for substrate cleavage assays, inhibitor IC50 profiling, and antibody validation alongside matched TPB antibody RP-ADAMTS12.
Expression system
HEK293
Cat. #
REC-ADAMTS12

In stock

SKU
REC-ADAMTS12
$498.00

Target Overview

ADAMTS-12 (A disintegrin and metalloproteinase with thrombospondin motifs 12; UniProt P58397) is a secreted, extracellular matrix-associated zinc metalloprotease belonging to the ADAMTS family. The full-length human protein spans 1,594 amino acids and contains the canonical ADAMTS domain architecture: a prodomain, a metalloprotease catalytic domain, a disintegrin-like domain, a central thrombospondin type-1 (TSP1) repeat, a cysteine-rich domain, a spacer domain, and additional C-terminal TSP1 repeats. This recombinant is produced in HEK293 mammalian cells, a choice that supports physiologically relevant N-linked glycosylation patterns and correct folding of the multi-domain structure — important considerations for researchers requiring active enzyme in substrate cleavage and inhibitor binding experiments. Documented substrates include cartilage oligomeric matrix protein (COMP), aggrecan, alpha-2-macroglobulin, and, as characterised in recent published methodology, the brain chondroitin sulphate proteoglycan neurocan (PMID 41917355). The enzyme is secreted into the extracellular space and associates with the extracellular matrix, consistent with its roles in connective tissue remodelling studied across cartilage, cancer, and placental biology contexts. This recombinant protein is used in vitro for direct enzymatic activity assays against defined substrates, for determination of inhibitor IC50 values, and as a positive control antigen in antibody validation workflows. Researchers requiring a matched antibody reagent for Western blot or IHC validation can pair this recombinant with Triple Point Biologics antibody RP-ADAMTS12, cross-referenced on the product page.

Background

ADAMTS-12 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protease family, a group of secreted, extracellular enzymes with well-established roles in the remodelling of the pericellular and extracellular matrix. The ADAMTS family as a whole is studied across a wide range of biological contexts — cartilage homeostasis, angiogenesis, coagulation, and tumour biology — and ADAMTS-12 has attracted particular research interest for its substrate repertoire and apparent context-dependent roles in tissue remodelling. In published musculoskeletal research, ADAMTS-12 has been characterised as a protease capable of degrading COMP (cartilage oligomeric matrix protein) and aggrecan, placing it alongside the aggrecanase-class ADAMTS members as a research target in cartilage matrix turnover. The enzyme also cleaves alpha-2-macroglobulin, a broad-spectrum protease inhibitor, which has implications for studies of protease regulation in the extracellular space. More recent published work has expanded the known substrate repertoire. Fontanil et al. (2026, PMID 41917355) describe a detailed assay methodology for measuring ADAMTS-12-mediated degradation of neurocan, a chondroitin sulphate proteoglycan abundant in the central nervous system extracellular matrix. This provides researchers with a well-defined in vitro substrate system for activity measurement and inhibitor characterisation using recombinant ADAMTS-12 protein. Beyond matrix biology, ADAMTS-12 expression has been studied in the context of tumour biology. The UniProt annotation notes anti-tumorigenic properties, consistent with published observations that ADAMTS-12 expression is altered in multiple cancer types. In ovarian cancer, transcriptomic studies have examined ADAMTS-12 among differentially expressed genes relevant to disease stratification (PMID 41643488). In placental biology, Chen et al. (2026, PMID 41876836) characterised ADAMTS-12 as a mediator through which decorin modulates trophoblast cell migration and invasion under inflammatory and metabolic stress conditions — identifying ADAMTS-12 as a functional node in a decorin-regulated signalling axis. Together, these published findings position recombinant ADAMTS-12 as a useful tool for researchers investigating extracellular matrix remodelling, protease–inhibitor interactions, substrate identification workflows, and the molecular mechanisms underlying its studied roles in cancer biology, joint tissue homeostasis, and placental physiology. All uses described here are for in vitro and ex vivo research applications only.

Applications

  • Substrate cleavage activity assay using neurocan, aggrecan, or COMP as defined substrates
  • Inhibitor IC50 determination against small-molecule or peptide ADAMTS-12 inhibitors
  • Antibody validation positive control for Western blot using matched antibody RP-ADAMTS12
  • Kinetic characterisation of ADAMTS-12 metalloprotease catalytic activity (Km, kcat determination)
  • Substrate identification and cleavage-site mapping by mass spectrometry
  • Protein–protein interaction studies with extracellular matrix components (e.g., COMP, alpha-2-macroglobulin)
  • Recombinant antigen standard for ELISA development and calibration

References

  1. Fontanil T et al. Assay for Neurocan-Degrading Activity of ADAMTS-12 Metalloprotease. Methods Mol Biol. 2026. doi:10.1007/978-1-0716-5218-3_7. PMID: 41917355
  2. Chen Q et al. Decorin inhibits the migration and invasion of the LPS + high glucose-induced primary trophoblast cell through ADAMTS12. In Vitro Cell Dev Biol Anim. 2026. doi:10.1007/s11626-026-01166-y. PMID: 41876836
  3. Thelagathoti RK et al. Detecting optimal biomarkers in ovarian cancer cells from high-dimensional mRNA expression data using machine learning. Comput Methods Programs Biomed. 2026. doi:10.1016/j.cmpb.2026.109263. PMID: 41643488
  4. Wu D et al. A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis. Theranostics. 2026. doi:10.7150/thno.129569. PMID: 42094592
  5. Kato Y et al. Rapid Drug Sensitivity Profiling via a Novel High-Success-Rate Culture Method for Patient-Derived Pancreatic Cancer: An Exploratory Preclinical Platform for Advancing Clinical Applications and Drug Development. Cells. 2026. doi:10.3390/cells15040313. PMID: 41744756

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight should I expect for recombinant ADAMTS-12 on SDS-PAGE or Western blot?

The full-length human ADAMTS-12 has a predicted polypeptide MW of ~178 kDa (1,594 aa; UniProt P58397). Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds appreciable mass — expect the apparent MW on reducing SDS-PAGE to run between 200–230 kDa. Under non-reducing conditions, migration may shift further due to disulfide-stabilized domain architecture. Always run alongside a broad-range ladder (10–250 kDa). Purity is >90% by SDS-PAGE, so the dominant band should be unambiguous at this position.

What processing or isoform state is the recombinant ADAMTS-12 supplied in — prodomain intact or mature form?

REC-ADAMTS12 is supplied as the processed, prodomain-removed mature form, meaning the catalytic domain is accessible and the enzyme is active upon thawing. ADAMTS-12 undergoes furin-mediated cleavage of its prodomain intracellularly; HEK293 expression faithfully recapitulates this step. If your experimental design specifically requires the zymogen/prodomain-intact form for activation studies, this product is not the appropriate choice. For most substrate cleavage, inhibitor binding, or antibody validation workflows, the mature active enzyme is the correct starting material.

What substrates does ADAMTS-12 cleave and which are best for a fluorometric activity assay?

Documented substrates for ADAMTS-12 include aggrecan (at the Glu373–Ala374 aggrecanase site), COMP, alpha-2-macroglobulin, and brain chondroitin sulfate proteoglycans. For a quantitative fluorometric assay, synthetic FRETS-aggrecan peptide substrates or the generic ADAMTS fluorogenic substrate Mca-KPILRGLFRK(Dnp)-NH2 are practical choices and have been used with other ADAMTS family members at Km values typically in the 5–50 µM range. Confirm that 5 mM CaCl2 is present in your assay buffer, as zinc metalloproteinase activity is calcium-dependent and CaCl2 is included in the TPB storage buffer for this reason.

What buffer conditions are optimal for ADAMTS-12 activity assays and are there any inhibitors to avoid?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is compatible with direct use in activity assays after dilution. For assay buffer, maintain pH 7.4–7.5 and keep CaCl2 at 1–5 mM. Avoid EDTA and EGTA entirely; even low micromolar concentrations chelate the active-site zinc and will abolish activity. Likewise, avoid 1,10-phenanthroline and broad-spectrum hydroxamate inhibitors (e.g., GM6001/ilomastat) in no-inhibitor control wells. DTT above 1 mM can also interfere with disulfide-dependent domain folding.

What starting concentration of recombinant ADAMTS-12 should I use for a substrate cleavage or IC50 inhibitor assay?

For initial substrate cleavage experiments, 1–10 nM enzyme is a practical starting range with synthetic fluorogenic peptide substrates at 10–50 µM. For IC50 determination with small-molecule inhibitors, keep enzyme concentration at or below your estimated Ki to avoid tight-binding artifacts (Cheng-Prusoff correction applies). For COMP or aggrecan cleavage monitored by Western blot or ELISA, 10–50 nM ADAMTS-12 over 2–16 hours at 37°C is commonly reported. Titrate enzyme concentration in pilot experiments rather than assuming published conditions from other ADAMTS paralogs translate directly.

Can I use REC-ADAMTS12 as a positive control for Western blot with the matched RP-ADAMTS12 antibody?

Yes — this is one of the most straightforward uses of the paired products. REC-ADAMTS12 and RP-ADAMTS12 are developed in the same TPB laboratory specifically to be compatible. Load 20–50 ng of recombinant protein per lane on a 6–8% SDS-PAGE gel (reducing conditions); the RP-ADAMTS12 rabbit polyclonal antibody should resolve a clean band at ~200–230 kDa. This positive control is particularly useful when validating RP-ADAMTS12 against cell lysates or tissue samples where endogenous ADAMTS-12 expression may be low. See the antibody product page at /anti-adamts-12-rabbit-polyclonal-antibody for recommended antibody dilutions.

How much recombinant ADAMTS-12 should I load for a Western blot positive control lane?

20–50 ng per lane is sufficient for a strong, clean signal with RP-ADAMTS12 on standard PVDF or nitrocellulose membranes. If you are co-running cell lysates (which will contain far less endogenous ADAMTS-12), load the recombinant in a flanking lane rather than mixing to avoid signal saturation obscuring the lysate bands. Use a 6% or 6–8% gradient gel to resolve the ~200–230 kDa glycoprotein efficiently. For semi-quantitative comparisons, prepare a 2-fold dilution series (50, 25, 12.5, 6.25 ng) to confirm linearity of your detection system before committing to experimental samples.

How should I handle, dilute, and store recombinant ADAMTS-12 to preserve activity over time?

REC-ADAMTS12 is shipped on dry ice and should be stored at -20°C immediately upon receipt. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) stabilizes the enzyme; do not dialyze away the glycerol or CaCl2. Aliquot upon first thaw into single-use volumes matched to your experiment — repeated freeze-thaw cycles cause measurable activity loss within 3 cycles. For dilutions, use the storage buffer or your assay buffer supplemented with 0.1% BSA (carrier protein) to prevent adsorptive losses at low concentrations (≤10 nM). Working dilutions should be prepared fresh and kept on ice.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS12 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →